Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Gains from Sales and Divestitures (2017 - 2025)

Iradimed has reported Gains from Sales and Divestitures over the past 9 years, most recently at $63105.0 for Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 23.57% to $63105.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $63105.0 through Dec 2025, up 23.57% year-over-year, with the annual reading at $63105.0 for FY2025, 23.57% up from the prior year.
  • Gains from Sales and Divestitures was $63105.0 for Q4 2025 at Iradimed, up from $51069.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $63105.0 in Q4 2025 and troughed at $4252.0 in Q4 2023.
  • The 5-year median for Gains from Sales and Divestitures is $51069.0 (2024), against an average of $43566.8.
  • Year-over-year, Gains from Sales and Divestitures plummeted 89.57% in 2023 and then skyrocketed 1101.06% in 2024.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $58650.0 in 2021, then crashed by 30.51% to $40758.0 in 2022, then plummeted by 89.57% to $4252.0 in 2023, then skyrocketed by 1101.06% to $51069.0 in 2024, then grew by 23.57% to $63105.0 in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Gains from Sales and Divestitures are $63105.0 (Q4 2025), $51069.0 (Q4 2024), and $4252.0 (Q4 2023).